On this World Chronic Myeloid Leukemia (CML) Day, Moldiag, a spin-off of Medical Biotechnology specializing in the production and marketing of medical diagnostic kits, looks back on its year of marketing the BCR-ABL diagnostic kit after its launch in 2023, to report on its progress.

As a reminder, Chronic Myeloid Leukemia (CML) is a blood cancer characterized by an elevated production of granulocytes (a type of white blood cell) by the bone marrow. Today, patients affected by this disease have effective treatment available (TKI – Tyrosine Kinase Inhibitors) provided that its dosage is adequate and tolerated.

However, the diagnostic management of CML is undoubtedly the key to diagnosing the disease, guiding treatment, and monitoring the patient.

Since the start of marketing the BCR-ABL Diagnostic Kit, Moldiag aims to make the test available through local production and accessible to patients through an innovative distribution model.

Indeed, price being a significant barrier according to patient associations, Moldiag commits with its medical laboratory partners to not exceed a public price of 1500 including taxes per analysis.

At this stage, the benefits observed for patients are significant. The test is continuously available, without the risk of stock shortages, thus ensuring easy access for all patients. Its affordable price allows for broader access to diagnosis. Additionally, patients benefit from more regular monitoring, promoting better disease management. Analysis results are obtained quickly, thereby providing increased reactivity in medical decision-making. These improvements contribute to an optimized and more secure patient experience.

In this context, Moldiag, a spin-off of the MAScIR Foundation, part of UM6P, will continue its efforts to extend its network of partner laboratories throughout all regions of the kingdom.

It is also worth noting that through the production of this test, which is set to become even more affordable, Moldiag contributes to the health security of the Kingdom as well as the national strategy for the generalization of medical coverage, national strategies in the manufacturing of health products and technologies, and continental public health strategies.

 

Media Contact

Fatima Zahra MARFOQ

Head of Communications and PR

Mobile: +212 665 46 88 44

Emails: f.marfoq@mascir.ma, fatimazahra.marfoq@um6p.ma